Introduction to Mesenteric Cystic Lymphangioma

Mesenteric cystic lymphangiomas (MCLs) represent rare, benign tumors of the lymphatic system. These lesions can develop anywhere from the duodenum to the rectum along the mesentery. While they are usually benign, their clinical presentation remains unpredictable. Consequently, clinicians often discover them incidentally during routine imaging or surgery for unrelated conditions. Effective mesenteric cystic lymphangioma management requires a high index of suspicion because these tumors often mimic malignant abdominal lesions.

Clinical Presentation and Diagnostic Challenges

Diagnosis preoperatively remains difficult due to the wide range of differential diagnoses. For instance, a recent case involved a 57-year-old male whose tumor mass appeared during a control ultrasonography. A subsequent CT scan revealed a massive cystic lesion measuring 75 × 100 × 92 mm near the Treitz angle. Furthermore, the tumor had a volume exceeding 430 cm³. These imaging findings are critical. However, they frequently overlap with other mesenteric cysts or even malignant soft-tissue tumors. Therefore, histopathological confirmation is always necessary to ensure diagnostic accuracy.

Effective Mesenteric Cystic Lymphangioma Management

Surgery stands as the treatment of choice for these rare lesions. Specifically, radical resection or total enucleation ensures the best patient outcomes. In the reported case, surgeons successfully performed a total enucleation of the mesenteric cyst. During the procedure, they observed a yellowish cystic wall and milky white fluid. This appearance is characteristic of chylous content within lymphatic spaces. Additionally, total excision prevents potential complications such as bowel obstruction, torsion, or recurrence. Following surgery, the patient typically experiences a smooth recovery. For example, the patient in this case study returned home after seven days and remained recurrence-free for over a year.

The Role of Immunohistochemistry

Immunohistochemical profiling provides the definitive evidence needed for a final diagnosis. Pathologists look for specific markers that highlight endothelial cells. Specifically, positive reactions for CD34, CD31, and podoplanin (D2-40) confirm the lymphatic origin. In contrast, negative reactions with CK AE1/AE3 and CK7 help rule out epithelial malignancies. Moreover, these markers allow clinicians to distinguish MCLs from other mimics like cystic mesotheliomas. This detailed analysis ensures that the mesenteric cystic lymphangioma management plan aligns with the benign nature of the tumor.

Frequently Asked Questions

What is the gold standard for mesenteric cystic lymphangioma management?

The gold standard is complete surgical resection or total enucleation. This approach effectively prevents recurrence and provides a definitive histopathological diagnosis.

Which imaging tools are most useful for diagnosing MCL?

Ultrasonography and CT scans are the primary tools used for detection. They typically show a thin-walled, multiloculated cystic mass, though MRI can offer better detail for fluid-filled spaces.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Fülöp ZZ et al. [Giant cystic lymphangioma of the small bowel mesentery]. Orv Hetil. 2026 May 17. doi: 10.1556/650.2026.33549. PMID: 42143684.

Watanabe A, Suzuki H, Kubo N, Kobayashi T, Araki K, Sasaki S. Abdominal lymphangiomas: Imaging features with pathologic correlation. AJR Am J Roentgenol. 2004;182:1485-91.

Mabrut JY, Grandjean JP, Henry L, Chappuis JP, Partensky C, Baulieux J, Adham M. Mesenteric cystic lymphangioma. Surgery. 2003;133(1):116-7.